Akèy › Maladi Crohn › Ohio
Etid klinik pou Maladi Crohn nan Ohio
30 etid pou Maladi Crohn ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
Ap rekriteVolontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07852273Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- ak 3 plis
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 29, 2026 · NCT06430801A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Cincinnati /ID# 265589, Cincinnati
- The Ohio State University /ID# 265577, Columbus
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06233461Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07769437Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
- Medical Associates Research Group-Site Number: 8400063, Columbus
- OSU Wexner Medical Center-Site Number: 8400077, Columbus
- ak 1 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 23, 2026 · NCT05995353Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
- Ohio Gastroenterology Group Inc.-8400006, Columbus
- ak 5 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Great Lakes Gastroenterology Research, LLC, Mentor
- ak 1 plis
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577843Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- Cleveland Clinic, Cleveland
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07680283A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07237516Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- UH Cleveland Medical Center /ID# 262188, Cleveland
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 24, 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
- UH/Rainbow Babies and Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Ap rekriteFaz 3
Laj 2 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou May 5, 2026 · NCT04779320Precise Infliximab Exposure and Pharmacodynamic Control
- Cincinnati Children's Hospital, Cincinnati
- Cleveland Clinic Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
Ap rekriteFaz 2/3
Laj 6 a 22 · Tout sèks · Mizajou May 5, 2026 · NCT05660746Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- OSU Inflammatory Bowel Disease Center, Hilliard
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 27, 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Dec 10, 2025 · NCT06721962Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekrite
Laj 13 a 17 · Tout sèks · Mizajou Nov 21, 2025 · NCT07195123Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Cleveland Clinic Foundation, Cleveland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Nov 12, 2025 · NCT06670638Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.